Literature DB >> 25302034

Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.

J S Hoch1, M B Brown2, C McMahon3, J Nanson4, L Rozmovits5.   

Abstract

In this interview with the patient representatives on the Expert Review Committee (perc) of the Pan-Canadian Oncology Drug Review (pcodr), those representatives offer their views about how to be a valuable contributing member of Canada's national cancer drug funding recommendation committee. The article seeks to inform readers, and especially clinicians, about pcodr from the perspective of the patient representatives.

Entities:  

Keywords:  Oncology drug funding; health economics; pcodr

Year:  2014        PMID： 25302034      PMCID： PMC4189566          DOI： 10.3747/co.21.2128

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  1 in total

1.  Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review.

Authors:  J S Hoch; M Sabharwal
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677
  1 in total
  5 in total

Review 1.  Promoting Scientist-Advocate Collaborations in Cancer Research: Why and How.

Authors:  Jeannine M Salamone; Wanda Lucas; Shelley B Brundage; Jamie N Holloway; Sherri M Stahl; Nora E Carbine; Margery London; Naomi Greenwood; Rosa Goyes; Deborah Charles Chisholm; Erin Price; Roberta Carlin; Susan Winarsky; Kirsten B Baker; Julia Maues; Ayesha N Shajahan-Haq
Journal:  Cancer Res       Date:  2018-08-17       Impact factor: 12.701

2.  Engaging Patient and Family Advisors in Health-Care System Planning: Experiences and Recommendations.

Authors:  Sarah Wheeler; Jenna MacKay; Lesley Moody; Junell D'Souza; Julie Gilbert
Journal:  J Patient Exp       Date:  2019-04-29

3.  Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?

Authors:  Jeffrey S Hoch; Jaclyn Beca; Mona Sabharwal; Scott W Livingstone; Anthony L A Fields
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

4.  Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).

Authors:  Lisa Masucci; Jaclyn Beca; Mona Sabharwal; Jeffrey S Hoch
Journal:  Pharmacoecon Open       Date:  2017-12

5.  Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada.

Authors:  Winson Y Cheung; Michelle K White; Martha S Bayliss; Angela Stroupe; Andrew Lovley; Bellinda L King-Kallimanis; Kathryn Lasch
Journal:  Support Care Cancer       Date:  2018-06-23       Impact factor: 3.603
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.